Dominick Arena has been both an Operating Partner and an Executive Advisor to Waterstreet Healthcare Partners a private equity company focused strictly on healthcare since 2006. He has more than 30 years of experience growing small start-ups and large multi-national corporations. Prior to Water Street, Dominick was president of Smiths Medical Critical Care, a leading global provider of medical devices.

Previously, he was President and CEO of Medex, Inc. At Medex, Dominick led a successful management buyout of the company and completed a number of strategic acquisitions to build the company into a leading global manufacturer of critical care medical products.

Dominick also served as the leader of three medical device manufacturing companies: Hudson Respiratory Care, Inc., Respiratory Care, Inc., and AnaMed International. He also led the healthcare business of the Furon Company.

Dominick began his career in the healthcare industry working for Baxter and The Kendall Corporation, where he was promoted to executive-level positions.

Dominick currently serves on the boards of Trudell Medical Limited, ZALEA, LLC, and Implantdata. He also is a member of the board of the Waldorf School of San Diego. Dominick received a bachelor’s degree in chemistry from LeMoyne College before serving his country in both the United States Army and the Central Intelligence Agency.

Dominick joined the Trudell Board in 2016. 

Peter Curry has had a successful 30-year career in medical devices spanning operations, sales, marketing and general management in Canada and the United States.

Most recently, Peter has retired from 19 years with CR BARD, holding various executive leadership roles. Throughout these roles, he effectively built strong performance cultures focused on sustainable growth and led new business expansions in China, Brazil, Turkey, Russia and Saudi. In addition, to his time at CR BARD, Peter held various roles at Zimmer Canada, VASCATH Inc.,  Ingram & Bell.

He graduated from Mechanical Engineering at Western University and obtained an Executive MBA from the Richard Ivey School of Business, Western University, London (ON).

Peter joined the Trudell Board in September 2018.

Rob Harris has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management. Rob most recently served as President and CEO of Tribute Pharmaceuticals. Prior to co-founding Tribute Pharmaceuticals, he was the President & CEO of Legacy Pharmaceuticals Inc. Rob also has previous experience at Biovail Corporation where as VP of Business Development he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Rob joined Biovail in 1997 as the GM of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division. Before Biovail, Rob worked in various senior commercial management positions during his twenty-year tenure at Wyeth (Ayerst) including its animal health group and has been involved in numerous product launches during his career.

Rob also serves as a member of the Board of Directors of Nuvo Pharmaceuticals Inc., Origin House and a former director at Tribute Pharmaceuticals and Aralez Pharmaceuticals Inc. He is also a member of the Board of Directors at Grey Wolf Animal Health, which is privately held.

Rob joined the Trudell Board in November 2018.

Guy Payette is the President and Founder of Innomar Strategies Inc., Canada’s leading integrated service provider for specialty pharmaceutical manufacturers. Innomar was sold to AmerisourceBergen.

With over 25 years of experience in sales, marketing, market access, and government relations, Guy’s career spans all facets of the pharmaceutical industry. Before Innomar, Guy was a senior executive at Boehringer Ingelheim for over 12 years.

Guy joined the Trudell Board in June 2016.

Marty Thrasher is currently President of FMT Consulting, a boutique management advisory and consulting firm specializing in the packaged goods industry. It is based in London (ON) and has been in business since 2004.

Marty is a seasoned international executive. After graduating in 1973 with an HBA from the Richard Ivey School of Business, Western University, London (ON), he spent over 30 years working around the globe for such blue-chip food companies as General Foods, McCormick & Co, Campbell Soup Co, and ConAgra Foods Inc. He lived and worked in Canada, Australia, Belgium and the USA. His responsibilities with Campbell Soup included positions as President, International and President, North America. At ConAgra, he was President of the Retail Products Co, a $9 billion business with over 30,000 employees.

As President of FMT Consulting, he has advised numerous organizations in a variety of industries in both North America and abroad.  He has successfully completed roles as interim Executive Chairman and CEO plus has extensive experience as a Director for both public and private company Boards.

Marty joined the Trudell Board in June 2017.

Since his retirement in 2014 from Boehringer Ingelheim Canada where he was President and CEO, Ted has taken on the role as a healthcare advisor and scholar based in Toronto (ON) and Lisbon (PT).  His is a Professor and Senior Fellow at University of Toronto’s School of Public Health.  Ted has earned a BSc from Quinnipiac College, an MPH from Yale, his DrPH from Columbia in NYC and MBA from Henley in London (UK).  He has published over 100 manuscripts and chapters in respiratory and drug development area; he has expertise in obstructive airway disease and has been a major contributor to the field of cough, cold & allergy. 

Ted joined the Trudell Board in 2014.